First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers
1 September 2020 (08:30 - 08:30)
Organised by:
Abstract
Slides
About the speaker
Bayer, Berlin (Germany)
6 More presentations in this session
Doctor P. Sansilvestri-Morel (Suresnes, FR)
Doctor P. Sulzgruber (Krems an der Donau, AT)
Access the full session
The Event
ESC Congress 2020
1 September 2020
08:30 CET
You may be interested in
Congress Presentation
Congress Presentation
